Glioma

The Ivy Brain Tumor Center is conducting a Phase 0/1 clinical trial to evaluate BDTX-1535, an experimental drug intended to block a key growth signal in patients with recurrent high-grade glioma, driven by EGFR (Epidermal Growth Factor Receptor) genetic aberrations.

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 3 study to evaluate ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.

A Phase 2 trial that studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to Bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient's response to treatment.

A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort.